Prof. Dr. med. Martin Schostak
Ihr Experte für urologische Onkologie von A-Z.
„Keine Erkrankung und kein Patient sind gleich. Der wichtigste Grundpfeiler meiner Behandlungsphilosophie ist daher die individuelle Auswahl der richtigen Therapie: Von der aktiven Überwachung über eine fokale Therapie bis hin zum chirurgischen Eingriff, einer Bestrahlung oder zur medikamentösen Behandlung. Die Lebenssituation und die individuellen Bedürfnisse des Patienten stehen dabei immer an erster Stelle.“
Kürzliche Veröffentlichungen
CONCLUSIONS AND CLINICAL IMPLICATIONS: While this trial has substantial limitations, the results support addition of RP as local therapy to BST in omPC. This trial is registered on ClinicalTrials.gov as NCT02454543.
CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of the online decision aid was associated with structural improvements, for example, significantly shorter doctor-patient consultation time. Our findings suggest stronger guideline adherence in the counseling process and promotion of health literacy. Successful implementation of our online decision aid in routine care can provide an example for solving this key obstacle for shared decision-making.
CONCLUSION: The risk of AKI was significantly higher after PAP with gentamicin compared to PAP with cefuroxime (OR: 6.25, 95% CI: 2.095-18.664, p = 0.001), suggesting that PAP with gentamicin should be avoided in RARP.
CONCLUSIONS AND CLINICAL IMPLICATIONS: TKI-based therapies are applied frequently in pRCC patients. Our data support the use of ICI plus TKI as a first-line standard for patients with pRCC. The major limitations were the retrospective data capture and short follow-up of our study. Additional analyses to tailor treatment strategies in patients with metastatic pRCC are warranted.
While multi-parametric magnetic resonance imaging (mpMRI) is known to be a specific and reliable modality for the diagnosis of non-metastatic prostate cancer (PC), positron emission tomography (PET) using ^(68)Ga labeled ligands targeting the prostate-specific membrane antigen (PSMA) is known for its reliable detection of prostate cancer, being the most sensitive modality for the assessment of the extra-prostatic extension of the disease and the establishment of a diagnosis, even before biopsy....
CONCLUSIONS: Over 20 years, the greatest ASMR shifted from AIAN to White individuals, with a nationally decreasing trend. The elderly and male populations continue to experience greater ASMRs. Overall, our findings provide key insights for identifying at-risk populations, guiding the development of targeted strategies to reduce disparities.
CONCLUSIONS: Physicians are more aware of F2FGs than OSGs. Before COVID-19, F2FGs played a minor role. One out of 4 patients used OSGs. One-third considered them helpful for treatment decision-making. OSG use rarely affects the final treatment decision. Urologists significantly underestimate OSG use by their patients. Peer-to-peer support is more likely to be received by patients with anxiety and depression. Comparative interventional trials are needed to recommend peer-to-peer interventions for...
CONCLUSIONS AND RELEVANCE: The use of microultrasonography-guided biopsy was noninferior to MRI/conventional ultrasonography fusion-guided biopsy for the detection of Gleason Grade Group 2 or higher prostate cancer in biopsy-naive men. Microultrasonography may provide an alternative to MRI for image-guided prostate biopsy.
The aim of active surveillance (AS) is to avoid overtreatment of clinically insignificant prostate cancer (PCa). It is now strongly recommended for patients diagnosed with localized low-risk PCa. Additionally, it can be considered for selected patients with localized PCa in the International Society of Urological Pathology (ISUP) group 2, provided patients have a favorable risk profile. This profile is histopathologically characterized by the presence of a low percentage of Gleason pattern 4 and...
CONCLUSION AND CLINICAL IMPLICATIONS: The study findings illustrate that qPCR consistently outperforms conventional histology in detecting lymph node metastases, regardless of biochemical recurrence. The hypothesis that qPCR is better at predicting later biochemical recurrence than conventional histology has not been confirmed.
CONCLUSIONS AND CLINICAL IMPLICATIONS: HRQoL did not significantly differ between the biweekly CBZ16 and the standard schedule. Additionally, onset of some adverse events was delayed. These results may increase health care providers' confidence in using CBZ in older patients with mCRPC who are denied chemotherapy.
Kürzliche Veröffentlichungen
CONCLUSIONS AND CLINICAL IMPLICATIONS: While this trial has substantial limitations, the results support addition of RP as local therapy to BST in omPC. This trial is registered on ClinicalTrials.gov as NCT02454543.
CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of the online decision aid was associated with structural improvements, for example, significantly shorter doctor-patient consultation time. Our findings suggest stronger guideline adherence in the counseling process and promotion of health literacy. Successful implementation of our online decision aid in routine care can provide an example for solving this key obstacle for shared decision-making.
CONCLUSION: The risk of AKI was significantly higher after PAP with gentamicin compared to PAP with cefuroxime (OR: 6.25, 95% CI: 2.095-18.664, p = 0.001), suggesting that PAP with gentamicin should be avoided in RARP.
CONCLUSIONS AND CLINICAL IMPLICATIONS: TKI-based therapies are applied frequently in pRCC patients. Our data support the use of ICI plus TKI as a first-line standard for patients with pRCC. The major limitations were the retrospective data capture and short follow-up of our study. Additional analyses to tailor treatment strategies in patients with metastatic pRCC are warranted.
While multi-parametric magnetic resonance imaging (mpMRI) is known to be a specific and reliable modality for the diagnosis of non-metastatic prostate cancer (PC), positron emission tomography (PET) using ^(68)Ga labeled ligands targeting the prostate-specific membrane antigen (PSMA) is known for its reliable detection of prostate cancer, being the most sensitive modality for the assessment of the extra-prostatic extension of the disease and the establishment of a diagnosis, even before biopsy....
CONCLUSIONS: Over 20 years, the greatest ASMR shifted from AIAN to White individuals, with a nationally decreasing trend. The elderly and male populations continue to experience greater ASMRs. Overall, our findings provide key insights for identifying at-risk populations, guiding the development of targeted strategies to reduce disparities.
CONCLUSIONS: Physicians are more aware of F2FGs than OSGs. Before COVID-19, F2FGs played a minor role. One out of 4 patients used OSGs. One-third considered them helpful for treatment decision-making. OSG use rarely affects the final treatment decision. Urologists significantly underestimate OSG use by their patients. Peer-to-peer support is more likely to be received by patients with anxiety and depression. Comparative interventional trials are needed to recommend peer-to-peer interventions for...
CONCLUSIONS AND RELEVANCE: The use of microultrasonography-guided biopsy was noninferior to MRI/conventional ultrasonography fusion-guided biopsy for the detection of Gleason Grade Group 2 or higher prostate cancer in biopsy-naive men. Microultrasonography may provide an alternative to MRI for image-guided prostate biopsy.
The aim of active surveillance (AS) is to avoid overtreatment of clinically insignificant prostate cancer (PCa). It is now strongly recommended for patients diagnosed with localized low-risk PCa. Additionally, it can be considered for selected patients with localized PCa in the International Society of Urological Pathology (ISUP) group 2, provided patients have a favorable risk profile. This profile is histopathologically characterized by the presence of a low percentage of Gleason pattern 4 and...
CONCLUSION AND CLINICAL IMPLICATIONS: The study findings illustrate that qPCR consistently outperforms conventional histology in detecting lymph node metastases, regardless of biochemical recurrence. The hypothesis that qPCR is better at predicting later biochemical recurrence than conventional histology has not been confirmed.
CONCLUSIONS AND CLINICAL IMPLICATIONS: HRQoL did not significantly differ between the biweekly CBZ16 and the standard schedule. Additionally, onset of some adverse events was delayed. These results may increase health care providers' confidence in using CBZ in older patients with mCRPC who are denied chemotherapy.
Expertise
Chirurgische Eingriffe
Weitreichende Erfahrung durch tausende offene, laparoskopische und robotergestützte Eingriffe an Prostata, Niere und Harnblase.
Fokale und Mikrotherapie
Vorsitzender des Arbeitskreises für Fokale und Mikrotherapie der Akademie der deutschen Urologen.
Medikamentöse Tumortherapie
Diverse Zusatzqualifikationen für eine Vielzahl moderner, medikamentenbasierter Tumorbehandlungen.
Leitliniengerechte Behandlung
Mitgestaltung der Best-Practices als langjähriger Angehöriger der S3-Leitlinienkommission für Prostatakrebs.
Management klinischer Studien
Durchführung und Leitung zahlreicher wissenschaftlicher Studien mit internationaler Ausprägung.
Medizinische Forschung
Über 240 peer-review Publikationen mit über 4500 Zitierungen. Reviewer für zahlreiche Fachzeitschriften.
Uroonkologische Studienzentrale
Die uroonkologische Studienzentrale der LOGICURO GmbH ist eine außeruniversitäre Forschungseinrichtung in Potsdam.
Unter der Leitung von Prof. Schostak führt das Team Phase-II- und Phase-III-Studien zu medikamentösen Therapien bei uroonkologischen Tumoren durch.
Die systemische Therapie urologischer Tumoren hat in den vergangenen zehn Jahren eine bemerkenswerte Entwicklung erfahren: Zahlreiche neue Wirkstoffe sind bereits zugelassen, weitere befinden sich in fortgeschrittener klinischer Prüfung.
Unser Anspruch ist es, wissenschaftliche Exzellenz mit langjähriger klinischer Expertise zu verbinden – um innovative Therapieoptionen frühzeitig für die Patientinnen und Patienten im südwestlichen Teil der Metropolregion Berlin & Potsdam verfügbar zu machen.